Valuation: AngioDynamics, Inc.

Market Cap 550M 482M 445M 415M 782M 52.02B 800M 5.35B 2.07B 25.66B 2.07B 2.02B 89.1B P/E 2026 *
-15.3x
P/E 2027 * -22.9x
Enterprise Value 550M 482M 445M 415M 782M 52.02B 800M 5.35B 2.07B 25.66B 2.07B 2.02B 89.1B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.67x
Free-Float
86.44%
Yield 2026 *
-
Yield 2027 * -
Jun. 17 AngioDynamics Receives FDA IDE Approval For RELIEF Feasibility Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment For Benign Prostatic Hyperplasia CI
Jun. 17 AngioDynamics Secures FDA Approval to Begin Benign Prostatic Hyperplasia Study MT
Jun. 10 AngioDynamics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 09:20 AM
May. 28 AngioDynamics says Palmetto GBA finalizes Medicare NanoKnife coverage from July 5, 2026 RE
May. 13 AngioDynamics Reports 'Durable Oncologic Control' in Study of NanoKnife for Intermediate-Risk Prostate Cancer MT
May. 13 AngioDynamics announces two-year Preserve trial data demonstrating durable NanoKnife IRE system outcomes in intermediate-risk prostate cancer RE
May. 13 AngioDynamics Announces Two-Year Preserve Trial Data Demonstrating Durable Nanoknife Ire System Outcomes In Intermediate-Risk Prostate Cancer CI
May. 01 The Us Food and Drug Administration Issues A Voluntary Class II Recall for the Soft-Vu Angiographic Catheter, Cobra (2), Non-Braided, Model No. 10714011 CI
May. 01 The Us Food and Drug Administration Issues A Voluntary Class Ii Recall for the Accuvu Angiographic Catheter, Omni Flush, Non-Braided, with 21 R/O Markers, Model No. 13709704 CI
May. 01 The Us Food and Drug Administration Issues A Voluntary Class Ii Recall for the Accuvu Angiographic Catheter, Pigtail, Non-Braided, with 21 R/O Markers, Model No. 13709804 CI
May. 01 The Us Food and Drug Administration Has Issued A Voluntary Class Ii Recall for the Accuvu Angiographic Catheter, Straight Flush, Non-Braided, with 10 R/O Markers, Model No. 13709604 CI
May. 01 The Us Food and Drug Administration Issues A Voluntary Class Ii Recall for the Soft-Vu Kumpe Angiographic Catheter, Non-Braided, Model Soft-Vu Kmp 4F X 40Cm 038 Nb 0Sh, Catalog No. 10710013 CI
May. 01 Fda Issues Voluntary Recall for Angiodynamics? Soft-Vu Berenstein Angiographic Catheter Due to Manufacturing Defect CI
1 day-1.49%
1 week+6.54%
Current month+14.98%
1 month+14.98%
3 months+21.10%
6 months+2.56%
Current year+2.80%
1 week 12.43
Extreme 12.43
13.79
1 month 10.86
Extreme 10.86
13.79
Current year 9.39
Extreme 9.39
13.79
1 year 8.36
Extreme 8.36
13.99
3 years 5.26
Extreme 5.26
13.99
5 years 5.26
Extreme 5.26
32
10 years 5.26
Extreme 5.26
32
Manager TitleAgeSince
Chief Executive Officer 62 2016-03-31
Director of Finance/CFO 51 2019-10-22
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Chairman 65 2014-04-28
Director/Board Member 67 2007-01-28
Director/Board Member 62 2016-03-31
Date Insider Type Main position Quantity % Market Cap.
25-10-20Buy

General Counsel

10,000 0.0247%
25-10-12Buy

Chief Financial Officer

890 0.0022%
25-10-08Buy

Chief Executive Officer

10,000 0.0247%
Change 5-day change 1-year change 3-year change Capi.($)
-1.49%+6.54%+34.97%+24.18% 550M
-1.50%+5.56%-31.01%-13.89% 161B
-0.06%+2.09%-5.92%-6.73% 104B
-1.57%+3.82%-5.93%+47.83% 54.8B
+0.23%-2.32%+50.80%+51.51% 53.31B
-0.47%+10.29%-9.17%-40.43% 42.76B
+1.90%+14.12% - - 33.49B
-0.23%+1.32%-18.94%-45.30% 27B
+1.09%+7.57%+62.05%-6.01% 25.06B
-1.13%+6.41%-10.70%-3.51% 20.78B
Average -0.32%+5.43%+7.35%+0.85% 52.28B
Weighted average by Cap. -0.54%+4.65%-5.70%-1.50%

Financials

2026 *2027 *
Net sales 314M 275M 254M 237M 446M 29.69B 456M 3.05B 1.18B 14.65B 1.18B 1.15B 50.85B 330M 289M 266M 249M 468M 31.16B 479M 3.21B 1.24B 15.37B 1.24B 1.21B 53.37B
Net income -36M -31.52M -29.1M -27.17M -51.15M -3.4B -52.31M -350M -135M -1.68B -135M -132M -5.83B -24.46M -21.42M -19.77M -18.47M -34.76M -2.31B -35.55M -238M -91.86M -1.14B -91.87M -89.85M -3.96B
Net Debt - -
Logo AngioDynamics, Inc.
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.
Employees
675
Date Price Change Volume
26-06-29 $13.20 -1.49% 341,079
26-06-26 $13.40 -1.90% 959,399
26-06-25 $13.66 +5.48% 313,256
26-06-24 $12.95 +4.69% 408,568
26-06-23 $12.37 -0.16% 286,194
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.20USD
Average target price
18.00USD
Spread / Average Target
+36.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANGO Stock